Natera: Squeezing The Last Drop From NIPT Growth Engine

  red_moon_rise/E+ via Getty Images Executive Summary The journey to bring molecular non-invasive prenatal screening/testing 'NIPT' to mainstream healthcare standards hasn't been easy. The sector faced and overcame the challenges of proving the accuracy and reliability of this tech. Natera (NASDAQ:NTRA) offers an opportunity to capitalize on the considerable groundwork already laid as we enter an era of widespread acceptance for all pregnant women, regardless of age, leveraging the established trust and ...